A Phase-II Study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in Patients with Refractory or Relapsed Aggressive and High Grade non-Hodgkin's Lymphoma

References

• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Jr, Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regiments for advanced Non-Hodgkin's lymphoma. N. Engl. J. Med. 1983; 32: 1002–1006
   Google Scholar
• Cabanillas F., Hagemeister F. B., McLaughlin P., Velasquez W. S., Riggs S., Fuller L., Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. J. Clin. Oncol. 1987; 5, 407–412
   Web of Science ®Google Scholar
• Ho A. D., Del Valle F., Rñckle H., Schwammborn J., Schlimok G., Hiddemann W., Meusers P., Thiel E., Dörken B., Hunstein W. Mitoxantrone and high-dose Cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. Cancer 1989; 64: 1388–1392
   PubMed Web of Science ®Google Scholar
• Connors J. M., Gascoyne R., Hoskins P., Klasa R., Klimo P., O'Reilly S. E. ACOP-12: 6 Dose/12 Week Chemotherapy for large cell lymphoma. Optimal combination of essential agents and brief treatment. PROC ASCO 1995; 14: 1238A
   Google Scholar
• Girouard C., Dufresne J., Imrie K., Prince M., Stewart A. K., Keating A., Crump M. Mini BEAM for relapsed or refractory lymphoma prior to ABMT. Blood 1995; 10, (Suppl 1), 203A
   Google Scholar
• Zuckerman K. S., LoBuglio A. F., Reeves J. A. Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high-dose Doxorubicin-containing regimen. J. Clin. Oncol. 1990; 8, 248–263
   PubMed Web of Science ®Google Scholar
• Villani F., Galimberti M., Comazzi R., Crippa F. Evaluation of cardiac toxicity of Idarubicin (4-Demethyldaunorubicin). Eur. J. Cancer Clin. Oncol. 1989; 25, 13–18
   PubMedGoogle Scholar
• Arcamone F., Bernardi L., Giardino P., Patelli B., Marco A., Casazza A. M., Pratesi G., Reggiani P. Synthesis and anti-tumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-dipidaunorubicin, and their B anomers. Cancer Treat. Rep. 1976; 60, 829–834
   PubMedGoogle Scholar
• Giuliani F. C., Spreafico F., Casazza A. M. Preclinical studies on new anthracyclines: antitumor toxicologic and pharmacologic properties. Anthracyclines and Cancer Therapy, H. H. Hansen. Excerpta Medica, Amsterdam 1983; 193–207
   Google Scholar
• Penco S., Casazza A. M., Franchi G., Barbieri B., Bellini O., Podesta A. Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines. Cancer Treat. Rep. 1983; 67, 665–673
   PubMedGoogle Scholar
• Christoffersen P. S., Rasmussen K. K., Hermansen K. Cardiovascular effects of Doxorubicin (Adriamycin) and 4-Demethoxydaunorubicin (Idarubicin) in the conscious rat. Pharmocol. Toxicol 1988; 62, 54–56
   PubMedGoogle Scholar
• Michieli M., Michelutti A., Damiani D., Pipan C., Raspadori D., Lauria F., Baccarani M. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivates. Leuk. Lymphoma 1993; 9, 255–264
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Michelutti A., Candoni A., Masolini P., Scaggiante B., Quadrifoglio F., Baccarani M. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica 1994; 79, 500–507
   Web of Science ®Google Scholar
• Ruutu T., Almqvist A., Hallman H., Honkanen T., Jarvenpaa E., Jarventie G., Koistinen P., Koivunen E., Lahtinen R., Lehtinen M. Oral induction and consilidation of acute myeloid leukemia with Etoposide, 6-Thioguanine, and Idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Leukemia 1994; 8, 11–15
   Web of Science ®Google Scholar
• Harousseau J. L., Reiffers J., Hurteloup P., Milpied N., Guy H., Rigal-Huguet F., Facon T., Dufour P., Ifrah N. Treatment of relapsed acute myeloid leukemia with Idarubicin and intermediate-dose Cytarabine. J. Clin. Oncol. 1989; 7, 45–49
   PubMed Web of Science ®Google Scholar
• Chisesi T., Capnist G., de Dominicis E., Dini E. A phase II study of Idarubicin (4-demethoxydaunorubicin) in advanced myeloma. Eur. J. Cancer Clin. Oncol. 1988; 24, 681–684
   PubMedGoogle Scholar
• Ganzina F., Pacciarini M. A., Di Pietro N. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. Invest. New Drugs 1986; 4: 85–105
   PubMed Web of Science ®Google Scholar
• Case D. C., Gerber M. C., Gams R., Crawford J., Votaw M. L., Higano C. S., Pruitt B. T., Gould J. Phase-II study of intravenous Idarubicin in unfavorable NHL. Cancer Res. 1992; 52, 3871–3874
   Web of Science ®Google Scholar
• Dufour P., Mors R., Lamy T. Idarubicin and high-dose Ara-C: A new promising salvage treatment in relapsed or refractory NHL. PROC ASCO 1993; 12, 1229A
   Google Scholar
• Taylor R. E., Mc Elwain T. J., Barrett A. Etoposide as a single agent in relapsed advanced lymphomas. A phase II study. Cancer Chemother. Pharmacol. 1982; 7: 175–177
   PubMed Web of Science ®Google Scholar
• Cabanillas F. Ifosfamide combinations in lymphoma. Sem. Oncol. 1990; 17 Suppl. 4: 58–62
   Web of Science ®Google Scholar
• Tigaud J. D., Demolombe S., Bastion Y., Bryon P. A., Coiffier B. Ifosfamide continuous infusion plus Etoposide in the treatment of elderly patients with aggressive lymphoma: A phase-II-study. Hematol. Oncol. 1991; 9: 225–233
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Hagemeister F. B., Bodey G. P., Freireich E. J. IMVP16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693–697
   PubMed Web of Science ®Google Scholar
• Walther J., Wilmanns W., Gerhartz H. H. IEVM chemotherapy with rhGM-CSF support for aggressive non-Hodgkin's lymphomas: a pilot study. Ann. Hematol. 1993; 66, 153–157
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Handbook for reporting results of cancer treatment. WHO Offset Publication, Geneva 1979; 48
   Google Scholar
• Scheulen M. E., Miller A. A., Heidrich T. Klinische Pharmakologie der niedrigdosierten wöchentlichen Behandlung mit 4′-Epiadriamycin (Epirubicin)—Vorläufige klinische und pharmakokinetische Ergebnisse. Aktuelle Onkologie 1985; 15: 44–61
   Google Scholar
• Shepherd J. D., Philips G. L. High-dose therapy for lymphoma. Current Opinion Oncol. 1993; 5: 797–704
   PubMedGoogle Scholar
• Gorin N. C. Autologous bone marrow transplantation in hematological malignancies. Am. J. Clin. Oncol. 1991; 14: 5–14
   PubMed Web of Science ®Google Scholar
• Wilson W. H., Bryant G., Bates S., Fojo A., Wittes R. E., Steinberg S. M. EPOCH Chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 1993; 11: 1573–1582
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Cabanillas F., Salvador P., McLaughlin P., Fridrik M., Tucker S., Jagannath S., Hagemeister F. B., Redman J. R., Swan F., Redman J. Effective salvage therapy for lymphoma with Cisplatin in combination with high-dose Ara-C and Dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Sparano J. A., Wiernik P. H., Leaf A, Dutcher J. P. Infusional Cyclophosphamide, Doxorubicin, and Etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J. Clin. Oncol. 1993; 11: 1071–79
   PubMed Web of Science ®Google Scholar
• Gianni A. M., Bonadonna G. High dose chemoradiotherapy for sensitive tumors: is sequential better than concurrent drug delivery?. Eur. J. Cancer Clin. Oncol. 1989; 25: 1027–1030
   PubMedGoogle Scholar
• Moskowitz C. H., Portlock C. S., Alvarez A., Yahalom J., Bertino J. R., Zelenetz A. D. Iceman (RT) A novel dose intense sequential chemoradiotherapy program for patients with refractory or relapsed intermediate grade lymphoma. Proc ASCO 1995; 14: 1266A
   Google Scholar
• Philip T., Guglielmi C., Chauvin F., Hagenbeek A., van der Lely J., Bron D., Sonneveld T., Gisselbrecht C., Cahn J. Y., Harousseau J. L., Coiffier B., Biron P., Somers R. Autologous bone marrow transplantation (ABMT) versus conventional chemotherapy (DHAP) in relapsed non Hodgkin lymphoma: Final analysis of the parma randomized study. PROC ACSO 1995; 14: 1220A
   Google Scholar
• Speth P. A., Minderman H., Haanen C. Idarubicin vs Daunorubicin: preclinical and clinical studies. Sem. Oncol. 1989; 16 (Suppl 2): 2–9
   Web of Science ®Google Scholar
• Reid J. M., Pendergrass T. W., Krailo M. D., Hammond G. D., Ames M. M. Plasma pharmacokinetics and cerebrospinal fluid concentrations of Idarubicin and Idarubicinol in pediatric leukemia patients: a childrens cancer study group. Cancer Res. 1990; 50: 6525–6528
   PubMed Web of Science ®Google Scholar
• Tidefelt U., Prenkert M., Paul C. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells. Blood 1995; 10 (Suppl 1): 3123A
   Google Scholar
• Dupont J., Garay C., Cacchione R. Treatment of refractory and relapsed lymphoma. MIZE protocol (Mesna-Ifosfamide, Idarubicin, and Etoposide). PROC ASCO 1994; 14: 1291A
   Google Scholar
• Zinzani P. L., Martelli M., Storti S., Musso M., Cantonetti M., Leone G., Cajozzo A., Papa G., Iannitto E., Perrotti A. Phase-III comparative trial CHOP vs CIOP in the treatment of advanced intermediate grade Non-Hodgkin's lymphoma. Leuk. and Lymphoma 1995; 19, 329–335
   Web of Science ®Google Scholar